New renal drug development to face chronic renal disease

Area of Science:

• Nephrology
• Pharmacology
• Drug Development

Background:

• Chronic kidney diseases (CKD) recognized by WHO in 2012 due to significant morbidity, mortality, and healthcare costs.
• Current CKD treatment relies on 1980s-era antihypertensive drugs, highlighting an unmet medical need.
• CKD presents a substantial market opportunity for pharmaceutical innovation.

Purpose of the Study:

• To explain the current feasibility of developing novel therapeutics for renal diseases.
• To focus on treatments targeting key pathogenic pathways in CKD.
• To review advancements enabling effective renal drug development.

Main Methods:

• Review of current scientific literature on renal drug development.
• Analysis of therapeutic strategies targeting inflammation and fibrosis in CKD.
• Examination of mechanisms driving CKD progression and organ function loss.

Main Results:

• Multiple preclinical and clinical approaches are available for developing effective renal therapeutics.
• Biomarkers are crucial for advancing drug development and understanding disease mechanisms.
• Surrogate indications for rare diseases can accelerate clinical validation of therapeutic targets.

Conclusions:

• Developing effective therapeutics for renal diseases is now plausible.
• Biomarker relevance and use of surrogate indications can expedite clinical development.
• These advancements hold the potential to revolutionize future CKD treatment paradigms.